Cancer Diagnostics Market by Diagnostic Type, Indication, Components, End-Use

List of Tables

The Cancer Diagnostics Market was valued at USD 29.95 billion in 2023, expected to reach USD 33.31 billion in 2024, and is projected to grow at a CAGR of 11.71%, to USD 65.06 billion by 2030.

The Cancer Diagnostics market encompasses a wide array of tests and procedures aimed at identifying cancerous cells, precancerous conditions, and overall tumor burden in patients. It includes imaging modalities like MRI and CT scans, blood tests, biopsies, and novel genetic and molecular diagnostic techniques. The necessity of cancer diagnostics stems from the growing prevalence of cancer globally, prompting the need for early detection and targeted treatment plans which can significantly improve patient outcomes and survival rates. This market's applications range across various cancer types, with end-users including hospitals, diagnostic laboratories, and research institutions. Key growth drivers include advancements in technology leading to more precise diagnostic methods, increased governmental support through funding and policy initiatives, and growing awareness and adoption of routine cancer screenings. Recent opportunities lie in the advent of AI-integrated diagnostics and liquid biopsy technologies, which offer minimally invasive, rapid, and highly accurate diagnostic options. The ongoing integration of genomics and personal medicine is also set to unlock new market potentials, giving businesses room to innovate in designing specific cancer-targeting diagnostics. However, challenges exist in the form of high costs of advanced diagnostic tools, stringent regulatory approvals, and limited access to healthcare infrastructure in developing regions. Additionally, the variability in cancer types and the complex nature of the disease create barriers to standardized diagnostic protocols. To foster innovation, investment in research focused on non-invasive diagnostic techniques and AI capabilities would be essential. Furthermore, partnerships between technology companies and healthcare providers can lead to breakthroughs in early detection and treatment effectiveness. Understanding the competitive landscape, dominated by key players who hold vast R&D capabilities, is crucial for businesses aiming to navigate and expand in this dynamic market, making continuous monitoring of emerging technologies and policy changes imperative for stakeholders.

KEY MARKET STATISTICS
Base Year [2023]	USD 29.95 billion
Estimated Year [2024]	USD 33.31 billion
Forecast Year [2030]	USD 65.06 billion
CAGR (%)	11.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Diagnostics Market

The Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Growing burden of cancer among younger and geriatric population
- Rising government initiatives and campaigns for cancer awareness
- Favorable reimbursement framework for cancer diagnosis
Market Restraints
- Associated high cost of cancer diagnostic equipment and lack of oncologists
Market Opportunities
- Deployement of innovative tools for cancer screening, detection, and diagnostics
- Integration of nanotechnology and nanomaterials in cancer diagnosis
Market Challenges
- Inadequate and false results of cancer diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Diagnostics Market

A detailed market share analysis in the Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Diagnostics Market

A strategic analysis of the Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson & Company, Bio-Techne Corporation, bioMerieux SA, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Perkin Elmer, Inc., Personal Genome Diagnostics Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Diagnostic Type, market is studied across Biopsy, Blood Chemistry Tests, and Imaging Tests. The Blood Chemistry Tests is further studied across Complete Blood Count (CBC), Cytogenetic Analysis, Immunophenotyping, Liquid Biopsy, Sputum Cytology, Tumor Marker Tests, and Urine Cytology. The Imaging Tests is further studied across Bone Scan, CT-Scan, Magnetic Resonance Imaging (MRI), Nuclear Scan, Positron Emission Tomography (PET) Scan, Ultrasound, and X-Rays.
Based on Indication, market is studied across Bladder Cancer, Blood Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.
Based on Components, market is studied across Consumables, Instruments, and Software.
Based on End-Use, market is studied across Diagnostic Laboratories, Hospitals, and Research Centers.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-436145BF8B0C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing burden of cancer among younger and geriatric population
  - 5.1.1.2. Rising government initiatives and campaigns for cancer awareness
  - 5.1.1.3. Favorable reimbursement framework for cancer diagnosis
- 5.1.2. Restraints
  - 5.1.2.1. Associated high cost of cancer diagnostic equipment and lack of oncologists
- 5.1.3. Opportunities
  - 5.1.3.1. Deployement of innovative tools for cancer screening, detection, and diagnostics
  - 5.1.3.2. Integration of nanotechnology and nanomaterials in cancer diagnosis
- 5.1.4. Challenges
  - 5.1.4.1. Inadequate and false results of cancer diagnostics
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Cancer Diagnostics Market, by Diagnostic Type

6.1. Introduction
6.2. Biopsy
6.3. Blood Chemistry Tests
- 6.3.1. Complete Blood Count (CBC)
- 6.3.2. Cytogenetic Analysis
- 6.3.3. Immunophenotyping
- 6.3.4. Liquid Biopsy
- 6.3.5. Sputum Cytology
- 6.3.6. Tumor Marker Tests
- 6.3.7. Urine Cytology
6.4. Imaging Tests
- 6.4.1. Bone Scan
- 6.4.2. CT-Scan
- 6.4.3. Magnetic Resonance Imaging (MRI)
- 6.4.4. Nuclear Scan
- 6.4.5. Positron Emission Tomography (PET) Scan
- 6.4.6. Ultrasound
- 6.4.7. X-Rays

7. Cancer Diagnostics Market, by Indication

7.1. Introduction
7.2. Bladder Cancer
7.3. Blood Cancer
7.4. Breast Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Pancreatic Cancer
7.10. Prostate Cancer
7.11. Skin Cancer

8. Cancer Diagnostics Market, by Components

8.1. Introduction
8.2. Consumables
8.3. Instruments
8.4. Software

9. Cancer Diagnostics Market, by End-Use

9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals
9.4. Research Centers

10. Americas Cancer Diagnostics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cancer Diagnostics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cancer Diagnostics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. New Funding to underpin development of Early Stage Cancer Platform Labmate Online
- 13.3.2. Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
- 13.3.3. Cancer diagnostics company GenoME Diagnostics bags £1.4M funding
- 13.3.4. Ibex's Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
- 13.3.5. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers
- 13.3.6. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment
- 13.3.7. Fujifilm India partners with Soorya Diagnostics LLP to launch CT Scan in Tirur
- 13.3.8. Biocare Medical Acquires Empire Genomics
- 13.3.9. Thermo Fisher ties up $2.6B deal for The Binding Site
- 13.3.10. Ibex Medical launches Galen 3.0 cancer diagnostics platform
- 13.3.11. Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
- 13.3.12. Karkinos Healthcare launches 'Advanced Centre For Cancer Diagnostics and Research'
- 13.3.13. BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
- 13.3.14. Becton Dickinson Acquires Spanish Clinical Flow Cytometry Firm Cytognos
- 13.3.15. EarlySign Announces Strategic Agreement to Commercialize AI Solution for Early Detection of Cancer
- 13.3.16. Cancer Diagnostics, Inc. Acquires Anatech, Ltd.
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Abbott Laboratories
2. Adaptive Biotechnologies Corporation
3. Agilent Technologies, Inc.
4. Becton, Dickinson & Company
5. Bio-Techne Corporation
6. bioMerieux SA
7. Castle Biosciences Inc.
8. Danaher Corporation
9. Exact Sciences Corporation
10. F. Hoffmann-La Roche Ltd.
11. GE Healthcare
12. Hologic Inc.
13. Illumina, Inc.
14. Johnson & Johnson Services, Inc.
15. Konica Minolta, Inc.
16. Koninklijke Philips N.V.
17. Myriad Genetics
18. Natera, Inc.
19. Perkin Elmer, Inc.
20. Personal Genome Diagnostics Inc.
21. Qiagen N.V.
22. Quest Diagnostics
23. Siemens Healthineers AG
24. Sysmex Corporation
25. Thermo Fisher Scientific, Inc.